Pharma's contentious inter partes reviews come under Supreme Court scrutiny
admin 27th November 2017 Uncategorised 0As several blockbuster drugs have faced patent challenges in recent years, many top drugmakers have pulled no punches in their opposition to the U.S. Patent and Trademark Office’s inter partes review process. Now, the issue is coming under Supreme Court scrutiny in a case that could have widespread implications for pharma.
More: Pharma's contentious inter partes reviews come under Supreme Court scrutiny
Source: fierce